Nicolas Sergeant is a full-time research director at Inserm UMRS 1172 Alzheimer & Tauopathies group. He is committed to understanding the mechanisms leading to neurodegeneration unraveling biomarkers and therapeutic targets for a family of neurological disorders named Tauopathies. He graduated in Biology of Aging in 1994 at the University of Paris Diderot VII. He focused his Ph.D. on characterizing the biochemical signature of neurological disorders, all having in standard a neurofibrillary degenerating process made of different sets of microtubule-associated Tau protein isoforms. He joined Inserm in 2000 as a full-time researcher and started investigating the relationship between the lesional processes of AD, namely the amyloid and Tau pathology. He developed all methods and tools to understand, find biological markers and therapeutic perspectives to correct or slow down neurodegenerative diseases, including Alzheimer’s Disease and Myotonic Dystrophy. He developed novel proteomics methods to analyze protein aggregates, a biology system for drug screening and structure-activity relationship, developed poly and monoclonals as well as transgenic models for the study of Tau splicing, also used for Tau seeding and propagation and expertise in medicinal chemistry, therapeutic strategy design, and immunological assays development together with basic biochemistry and molecular biology skills. He has eleven patents and contributed to Pharmaceutical companies (Alzprotect, Sanofi, Innogenetics, Pfizer, Biogen, Servier …) to develop biomarkers, small drug molecules against Tauopathies and AD – one, Ezeprogind who recently succeeded the clinical Phase II for Supranuclear Gas Palsy – and a gene therapy for myotonic dystrophy; a neuromuscular disorder belonging the family of RNAopathies which associates a mis-splicing of Tau, the development of neurofibrillary degeneration and cognitive deficits. Nicolas Sergeant has published more than a hundred articles, and he is a member of the operational committee of Foundation Plan Alzheimer, a member of the Scientific Committee of L’Association France Alzheimer, a member of the AFM task force on myotonic dystrophy and a member of the scientific committee of the international myotonic dystrophy congress and associate editor for Frontiers in Neurology and Exploration of Neuroprotective Therapy Journal.